Unnati Pharmax

Mytera 250 mg Tablets
Composition: Abiraterone Acetate 250 mg
International Trade Name: Zytiga®

Mytera 250 mg Tablets are a high-quality formulation of Abiraterone Acetate, a selective androgen biosynthesis inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, Mytera Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of prostate cancer.

Abiraterone acetate is a potent inhibitor of the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), which plays a key role in androgen production. By suppressing androgen synthesis in the testes, adrenal glands, and tumor tissue, Mytera helps reduce testosterone levels and slows tumor growth and disease progression. This targeted hormonal therapy is typically administered in combination with prednisone or prednisolone.

Mytera 250 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), especially in patients who are receiving or have progressed on androgen deprivation therapy (ADT).

Abiraterone acetate 250 mg tablets, Mytera, Zytiga® generic, prostate cancer treatment, androgen biosynthesis inhibitor, hormonal oncology therapy, anticancer drug exporter India, and prostate cancer medicine manufacturer India.

Mytera Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Abiranamo Tablets
Composition: Abiraterone Acetate Tablets (250 mg / 500 mg – as applicable)
International Trade Name: Zytiga®

Abiranamo is a high-quality Abiraterone Acetate formulation, a generic equivalent of the internationally recognized androgen biosynthesis inhibitor marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, Abiranamo Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in prostate cancer therapy.

Abiraterone acetate is a selective and irreversible inhibitor of the CYP17 enzyme, which plays a crucial role in androgen production. By blocking androgen synthesis in the testes, adrenal glands, and tumor microenvironment, Abiranamo helps reduce circulating androgen levels, thereby slowing tumor growth and disease progression in hormone-dependent prostate cancer.

Abiranamo is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). It is commonly administered in combination with prednisone or prednisolone as part of a comprehensive hormonal therapy regimen.

Abiraterone acetate tablets, Abiranamo, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, hormonal oncology therapy, anticancer tablets exporter India, and oncology pharmaceutical manufacturer India.

Abiranamo Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

 

Indenza – Enzalutamide Capsules
Composition: Enzalutamide
International Trade Name: Xtandi®

Indenza is a high-quality formulation of Enzalutamide, a non-steroidal androgen receptor signaling inhibitor and a generic equivalent of the internationally recognized product marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Indenza is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide works by blocking multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By effectively inhibiting these mechanisms, Indenza helps prevent prostate cancer cell proliferation and slows disease progression, even in patients resistant to conventional androgen deprivation therapy (ADT).

Indenza is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). It can be prescribed as monotherapy or in combination with ongoing ADT.

Enzalutamide capsules, Indenza, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Indenza is manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

 

Mytera 500 Tablets
Composition: Abiraterone Acetate 500 mg
International Trade Name: Zytiga®

Mytera 500 is a high-quality Abiraterone Acetate 500 mg tablet, a generic equivalent of the internationally recognized androgen biosynthesis inhibitor marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, Mytera Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of prostate cancer.

Abiraterone acetate is a potent, selective inhibitor of the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), which is essential for androgen production. By suppressing androgen synthesis in the testes, adrenal glands, and tumor tissue, Mytera 500 helps reduce circulating testosterone levels, thereby slowing tumor growth and disease progression. This targeted hormonal therapy is typically administered in combination with prednisone or prednisolone.

Mytera 500 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), especially in patients who are receiving or have progressed on androgen deprivation therapy (ADT).

Abiraterone acetate 500 mg tablets, Mytera tablets, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Mytera Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Abirapro 250 mg Tablets
Composition: Abiraterone Acetate 250 mg
International Trade Name: Zytiga®

Abirapro 250 mg Tablets are a high-quality formulation of Abiraterone Acetate, a selective androgen biosynthesis inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, Abirapro Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of prostate cancer.

Abiraterone acetate is a potent inhibitor of the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), which plays a key role in androgen production. By suppressing androgen synthesis in the testes, adrenal glands, and tumor tissue, Abirapro helps reduce testosterone levels and slows tumor growth and disease progression. This targeted hormonal therapy is typically administered in combination with prednisone or prednisolone.

Abirapro 250 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), especially in patients who are receiving or have progressed on androgen deprivation therapy (ADT).

Abiraterone acetate 250 mg tablets, Abirapro, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, hormonal oncology therapy, anticancer drug exporter India, and prostate cancer medicine manufacturer India.

 

Abirapro Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Samptica 500 Tablets
Composition: Abiraterone Acetate 500 mg
International Trade Name: Zytiga®, Yonsa®

Samptica 500 Tablets are a high-quality formulation of Abiraterone Acetate 500 mg, a selective androgen biosynthesis inhibitor, and a generic equivalent of the internationally recognized products marketed under the brand names Zytiga® and Yonsa®. Manufactured in WHO-GMP certified facilities, Samptica Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of prostate cancer.

Abiraterone acetate works by selectively inhibiting the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), which is critical for androgen production. By suppressing androgen synthesis in the testes, adrenal glands, and tumor tissue, Samptica 500 helps reduce circulating testosterone levels, thereby slowing tumor growth and disease progression. This targeted hormonal therapy is typically administered in combination with prednisone or prednisolone.

Samptica 500 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), especially in patients who are receiving or have progressed on androgen deprivation therapy (ADT).

Abiraterone acetate 500 mg tablets, Samptica tablets, Zytiga generic, Yonsa generic, prostate cancer treatment, androgen biosynthesis inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Samptica Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Abirakast 250 mg Tablets
Composition: Abiraterone Acetate 250 mg Tablets
International Trade Name: Zytiga®

Abirakast 250 is a high-quality Abiraterone Acetate 250 mg tablet, a generic equivalent of the internationally recognized androgen biosynthesis inhibitor marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, Abirakast Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of prostate cancer.

Abiraterone acetate is a potent, selective inhibitor of the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), which plays a key role in androgen biosynthesis. By suppressing androgen production in the testes, adrenal glands, and tumor tissues, Abirakast 250 helps reduce testosterone levels and slow disease progression. This targeted hormonal therapy is commonly administered in combination with prednisone or prednisolone.

Abirakast 250 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), particularly in patients undergoing or previously treated with androgen deprivation therapy (ADT).

Abiraterone acetate 250 mg tablets, Abirakast tablets, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, oncology hormonal therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Abirakast Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Bdron 250 Tablets
Composition: Abiraterone Acetate 250 mg
International Trade Name: Zytiga®

Bdron 250 Tablets are a high-quality formulation of Abiraterone Acetate 250 mg, a selective androgen biosynthesis inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, Bdron Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of prostate cancer.

Abiraterone acetate works by selectively inhibiting the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), which is essential for androgen production. By suppressing androgen synthesis in the testes, adrenal glands, and tumor tissue, Bdron 250 helps reduce circulating testosterone levels, thereby slowing tumor growth and disease progression. This targeted hormonal therapy is typically administered in combination with prednisone or prednisolone.

Bdron 250 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), especially in patients who are receiving or have progressed on androgen deprivation therapy (ADT).

Abiraterone acetate 250 mg tablets, Bdron tablets, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Bdron Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Xbira 500 Tablets
Composition: Abiraterone Acetate 500 mg
International Trade Name: Zytiga®

Xbira 500 Tablets are a high-quality formulation of Abiraterone Acetate 500 mg, a selective androgen biosynthesis inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, Xbira Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of prostate cancer.

Abiraterone acetate works by selectively inhibiting the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), which is essential for androgen production. By suppressing androgen synthesis in the testes, adrenal glands, and tumor tissue, Xbira 500 helps reduce circulating testosterone levels, thereby slowing tumor growth and disease progression. This targeted hormonal therapy is typically administered in combination with prednisone or prednisolone.

Xbira 500 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), especially in patients who are receiving or have progressed on androgen deprivation therapy (ADT).

Abiraterone acetate 500 mg tablets, Xbira tablets, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Xbira Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Enzalutamide Capsules
Composition: Enzalutamide (Strength as per prescription)
International Trade Name: Xtandi®

Enzalutamide Capsules are a high-quality formulation of Enzalutamide, a potent non-steroidal androgen receptor inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, these capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide works by blocking multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By effectively inhibiting these mechanisms, Enzalutamide prevents prostate cancer cell proliferation and slows disease progression, even in patients resistant to conventional androgen deprivation therapy (ADT).

Enzalutamide Capsules are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). It can be prescribed as monotherapy or in combination with ongoing ADT.

Enzalutamide capsules, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Enzalutamide Capsules are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Enzandro 160 mg Tablets
Composition: Enzalutamide 160 mg
International Trade Name: Xtandi®

Enzandro 160 mg Tablets are a high-quality formulation of Enzalutamide, a non-steroidal androgen receptor signaling inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Enzandro is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide works by blocking multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By effectively inhibiting these mechanisms, Enzandro 160 mg helps prevent prostate cancer cell proliferation and slows disease progression, even in patients resistant to conventional androgen deprivation therapy (ADT).

Enzandro 160 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). They can be prescribed as monotherapy or in combination with ongoing ADT.

Enzalutamide 160 mg tablets, Enzandro, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Enzandro Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Xylutide 40 mg Capsules
Composition: Enzalutamide 40 mg
International Trade Name: Xtandi®

Xylutide 40 mg Capsules are a high-quality formulation of Enzalutamide, a non-steroidal androgen receptor inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Xylutide is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide works by blocking multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By inhibiting these mechanisms, Xylutide 40 mg helps prevent prostate cancer cell proliferation and slows disease progression, even in patients resistant to conventional androgen deprivation therapy (ADT).

Xylutide 40 mg Capsules are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). It can be prescribed as monotherapy or in combination with ongoing androgen deprivation therapy.

Enzalutamide 40 mg capsules, Xylutide, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Xylutide is manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Enzalieva 40mg Capsules/Tablets
Composition: Enzalutamide 40 mg
International Trade Name: Xtandi®

Enzalieva 40 is a high-quality Enzalutamide 40 mg formulation, a generic equivalent of the internationally recognized androgen receptor inhibitor marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Enzalieva is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in prostate cancer management.

Enzalutamide is a next-generation androgen receptor signaling inhibitor that blocks multiple steps in the androgen receptor pathway, including androgen binding, nuclear translocation, and DNA interaction. By effectively suppressing androgen-driven tumor growth, Enzalieva 40 helps slow disease progression and improve clinical outcomes in patients with advanced prostate cancer.

Enzalieva 40 mg is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). It is commonly prescribed for patients who have progressed on or are receiving androgen deprivation therapy (ADT), offering a potent oral alternative to conventional chemotherapy.

Enzalutamide 40 mg capsules/tablets, Enzalieva, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer drug exporter India, and oncology pharmaceutical manufacturer India.

Enzalieva 40 is manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Enzamide 80 mg Capsules
Composition: Enzalutamide 80 mg
International Trade Name: Xtandi®

Enzamide 80 mg Capsules are a high-quality formulation of Enzalutamide, a potent non-steroidal androgen receptor inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Enzamide is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide works by blocking multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By effectively inhibiting these mechanisms, Enzamide prevents prostate cancer cell proliferation and slows disease progression, even in patients resistant to conventional androgen deprivation therapy (ADT).

Enzamide 80 mg Capsules are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). It can be prescribed as monotherapy or in combination with ongoing ADT.

Enzalutamide 80 mg capsules, Enzamide capsules, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Enzamide Capsules are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Enzabuzz 40 mg Capsules/Tablets
Composition: Enzalutamide 40 mg
International Trade Name: Xtandi®

Enzabuzz 40 is a high-quality Enzalutamide 40 mg formulation, a generic equivalent of the internationally recognized androgen receptor signaling inhibitor marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Enzabuzz is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide is a potent, non-steroidal androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By effectively inhibiting these mechanisms, Enzabuzz 40 helps prevent prostate cancer cell growth and proliferation, even in cases resistant to conventional androgen deprivation therapy.

Enzabuzz 40 mg is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). It is typically prescribed as monotherapy or in combination with ongoing androgen deprivation therapy (ADT).

Enzalutamide 40 mg capsules, Enzabuzz, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Enzabuzz is manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Azel 40 mg Capsules
Composition: Enzalutamide 40 mg
International Trade Name: Xtandi®

Azel 40 mg Capsules are a high-quality formulation of Enzalutamide, a non-steroidal androgen receptor signaling inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Azel Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide works by blocking multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By effectively inhibiting these mechanisms, Azel 40 mg helps prevent prostate cancer cell proliferation and slows disease progression, even in patients resistant to conventional androgen deprivation therapy (ADT).

Azel 40 mg Capsules are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). They can be prescribed as monotherapy or in combination with ongoing ADT.

Enzalutamide 40 mg capsules, Azel, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Azel Capsules are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

APNAT 60 mg Tablets
Composition: Apalutamide 60 mg
International Trade Name: Erleada®

APNAT 60 mg Tablets are a high-quality formulation of Apalutamide, a non-steroidal androgen receptor inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Erleada®. Manufactured in WHO-GMP certified facilities, APNAT Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of prostate cancer.

Apalutamide works by binding to androgen receptors and inhibiting androgen-driven signaling pathways, thereby preventing the growth and proliferation of prostate cancer cells. This targeted therapy is effective in slowing disease progression in patients with castration-resistant and non-metastatic prostate cancer.

APNAT 60 mg Tablets are primarily indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and may also be used in selected patients with metastatic hormone-sensitive prostate cancer (mHSPC) as part of combination therapy.

Apalutamide 60 mg tablets, APNAT, Erleada® generic, androgen receptor inhibitor, prostate cancer treatment, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

APNAT Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Ibyra 100 mg Tablets
Composition: Olaparib 100 mg
International Trade Name: Lynparza®

Ibyra 100 mg Tablets are a high-quality formulation of Olaparib, a potent poly (ADP-ribose) polymerase (PARP) inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Lynparza®. Manufactured in WHO-GMP certified facilities, Ibyra is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of BRCA-mutated cancers.

Olaparib works by inhibiting the PARP enzyme, which plays a critical role in DNA repair in cancer cells. By blocking DNA repair mechanisms, Ibyra induces cancer cell death, especially in tumors with BRCA1 or BRCA2 mutations, making it an effective targeted therapy for patients with specific genetic profiles.

Ibyra 100 mg Tablets are primarily indicated for the treatment of BRCA-mutated ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, either as monotherapy or as maintenance therapy following response to platinum-based chemotherapy.

Olaparib 100 mg tablets, Ibyra tablets, Lynparza generic, PARP inhibitor, targeted oncology therapy, anticancer medicine exporter India, and pharmaceutical manufacturer India.

Ibyra Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Ribaxa 150 mg Tablets
Composition: Olaparib 150 mg
International Trade Name: Lynparza®

Ribaxa 150 mg Tablets are a high-quality formulation of Olaparib, a potent poly (ADP-ribose) polymerase (PARP) inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Lynparza®. Manufactured in WHO-GMP certified facilities, Ribaxa is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of BRCA-mutated cancers.

Olaparib works by inhibiting the PARP enzyme, which plays a critical role in DNA repair in cancer cells. By blocking DNA repair mechanisms, Ribaxa induces apoptosis in cancer cells, especially in tumors with BRCA1 or BRCA2 mutations, making it an effective targeted therapy for patients with specific genetic profiles.

Ribaxa 150 mg Tablets are primarily indicated for the treatment of BRCA-mutated ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, either as monotherapy or as maintenance therapy following response to platinum-based chemotherapy.

Olaparib 150 mg tablets, Ribaxa tablets, Lynparza generic, PARP inhibitor, targeted oncology therapy, anticancer medicine exporter India, and pharmaceutical manufacturer India.

Ribaxa Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Parbraze 150 mg Tablets
Composition: Olaparib 150 mg
International Trade Name: Lynparza®

Parbraze 150 mg Tablets are a high-quality formulation of Olaparib, a potent poly (ADP-ribose) polymerase (PARP) inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Lynparza®. Manufactured in WHO-GMP certified facilities, Parbraze is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of BRCA-mutated cancers.

Olaparib works by inhibiting the PARP enzyme, which plays a critical role in DNA repair in cancer cells. By blocking DNA repair mechanisms, Parbraze induces apoptosis in cancer cells, especially in tumors with BRCA1 or BRCA2 mutations, making it an effective targeted therapy for patients with specific genetic profiles.

Parbraze 150 mg Tablets are primarily indicated for the treatment of BRCA-mutated ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, either as monotherapy or as maintenance therapy following response to platinum-based chemotherapy.

Olaparib 150 mg tablets, Parbraze tablets, Lynparza generic, PARP inhibitor, targeted oncology therapy, anticancer medicine exporter India, and pharmaceutical manufacturer India.

Parbraze Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

OLANAMO 150 mg Tablets
Composition: Olaparib 150 mg
International Trade Name: Lynparza®

OLANAMO 150 mg Tablets are a high-quality formulation of Olaparib, a potent poly (ADP-ribose) polymerase (PARP) inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Lynparza®. Manufactured in WHO-GMP certified facilities, OLANAMO is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of BRCA-mutated cancers.

Olaparib works by inhibiting the PARP enzyme, which is essential for DNA repair in cancer cells. By blocking DNA repair mechanisms, OLANAMO induces apoptosis in cancer cells, especially in tumors with BRCA1 or BRCA2 mutations, making it an effective targeted therapy for patients with specific genetic profiles.

OLANAMO 150 mg Tablets are primarily indicated for the treatment of BRCA-mutated ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, either as monotherapy or as maintenance therapy following response to platinum-based chemotherapy.

Olaparib 150 mg tablets, OLANAMO tablets, Lynparza generic, PARP inhibitor, targeted oncology therapy, anticancer medicine exporter India, and pharmaceutical manufacturer India.

OLANAMO Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Olabir 150mg Tablets
Composition: Olaparib Tablets 150mg
International Trade Name: Lynparza®

Olabir 150 is a high-quality Olaparib Tablets 150mg, a generic equivalent of the internationally recognized PARP inhibitor marketed under the brand name Lynparza®. Manufactured in WHO-GMP certified facilities, Olabir Tablets are supplied by trusted pharmaceutical manufacturers and exporters from India to support advanced global oncology treatment programs.

Olaparib is a targeted poly (ADP-ribose) polymerase (PARP) inhibitor that exploits defects in DNA repair pathways, particularly in BRCA-mutated and homologous recombination–deficient (HRD) cancers, leading to selective cancer cell death. Olabir 150mg Tablets are primarily indicated for the treatment of ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer, either as monotherapy or maintenance therapy following platinum-based chemotherapy, as per approved clinical guidelines.

Olabir Olaparib Tablets 150mg are widely used in oncology hospitals, cancer specialty centers, and government oncology programs due to their proven efficacy, oral convenience, and compatibility with international treatment protocols.

Olaparib tablets 150mg, Olabir tablets, Lynparza generic, PARP inhibitor price, BRCA-mutated cancer treatment, ovarian cancer maintenance therapy, targeted oncology drug exporter India, oncology pharmaceutical manufacturer India.

Olabir 150 Olaparib Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, bioavailability, and long-term stability. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory and quality documentation, making it suitable for international pharmaceutical distributors, oncology clinics, hospitals, and institutional cancer treatment programs worldwide.

Luprova 22.5 mg Depot Injection
Composition: Leuprolide Acetate 22.5 mg
International Trade Name: Lupron®

Luprova 22.5 mg Depot Injection is a high-quality, long-acting formulation of Leuprolide Acetate, a synthetic gonadotropin-releasing hormone (GnRH) agonist, and a generic equivalent of the internationally recognized product marketed under the brand name Lupron®. Manufactured in WHO-GMP certified facilities, Luprova is supplied by trusted pharmaceutical exporters from India to support advanced global oncology and hormone therapy programs, particularly in the management of prostate cancer and other hormone-sensitive conditions.

Leuprolide acetate works by initially stimulating and then downregulating pituitary GnRH receptors, leading to suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in a significant reduction of testosterone in men and estrogen in women, providing effective hormone therapy for conditions such as advanced prostate cancer, endometriosis, uterine fibroids, and assisted reproduction protocols.

Luprova 22.5 mg Depot Injection is primarily indicated for advanced prostate cancer, endometriosis, uterine fibroids, and other hormone-dependent conditions requiring sustained hormone suppression over a 3-month period.

Leuprolide acetate 22.5 mg depot injection, Luprova, Lupron generic, GnRH agonist therapy, prostate cancer treatment, hormone-sensitive therapy, anticancer injectable exporter India, and pharmaceutical manufacturer India.

Luprova is manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Ahabir 500 mg Tablets
Composition: Abiraterone Acetate 500 mg Tablets
International Trade Name: Zytiga®

Ahabir 500 is a high-quality Abiraterone Acetate 500 mg tablet, a generic equivalent of the internationally recognized androgen biosynthesis inhibitor marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, Ahabir Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the treatment of prostate cancer.

Abiraterone acetate is a potent, selective inhibitor of the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), which plays a critical role in androgen production. By suppressing androgen synthesis in the testes, adrenal glands, and tumor tissue, Ahabir 500 helps significantly reduce testosterone levels, thereby slowing tumor growth and disease progression. This targeted hormonal therapy is typically administered in combination with prednisone or prednisolone.

Ahabir 500 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), especially in patients who are receiving or have progressed on androgen deprivation therapy (ADT).

Abiraterone acetate 500 mg tablets, Ahabir tablets, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, oncology hormonal therapy, anticancer drug exporter India, and prostate cancer medicine manufacturer India.

Ahabir Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

INDENZA 160 MG 
Composition: ENZALUTAMIDE 160
International Trade Name: Xtandi®

Indenza Enzalutamide 160 mg (Xtandi) is an oral anticancer medication used in the treatment of advanced prostate cancer. It contains Enzalutamide 160 mg, a potent androgen receptor inhibitor that helps slow the growth and spread of prostate cancer cells. The reference brand Xtandi, developed by Astellas Pharma in collaboration with Pfizer, is widely recognized as a breakthrough therapy in prostate cancer care. Indenza provides the same active ingredient and therapeutic action, manufactured under strict pharmaceutical quality standards for oncology treatment.
Enzalutamide works by blocking the effects of male hormones (androgens) that promote the growth of prostate cancer cells. It prevents androgens from binding to their receptors and stops the signals that stimulate cancer cell multiplication. This targeted mechanism helps slow disease progression and may extend survival in patients with metastatic or castration-resistant prostate cancer. Because of its effectiveness, enzalutamide is an important component of modern prostate cancer management.
Indenza Enzalutamide 160 mg is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), as prescribed by an oncologist. The medicine is taken orally once daily, with or without food, at the same time each day. Tablets should be swallowed whole with water and not crushed or chewed. The exact duration of treatment depends on the patient’s response and overall medical condition.
Patients receiving Indenza require regular medical monitoring, including blood tests and clinical assessments, to evaluate treatment effectiveness and detect side effects. Common side effects may include fatigue, weakness, hot flashes, high blood pressure, dizziness, and decreased appetite. In rare cases, seizures or serious neurological effects may occur. Patients should immediately report symptoms such as confusion, severe headache, or unusual weakness to their healthcare provider.
Important safety precautions must be observed during therapy. Indenza is not intended for use in women or children. Pregnant women should avoid handling the tablets, as exposure may harm the unborn baby. Men taking this medication should use effective contraception during treatment and for a recommended period afterward. Patients with a history of seizures, heart disease, or liver problems should inform their doctor before starting therapy.
Indenza Enzalutamide 160 mg tablets are supplied in secure packaging to maintain stability and potency and should be stored in a cool, dry place away from direct sunlight. The product is manufactured according to recognized international pharmaceutical standards, ensuring reliability and consistent quality in clinical use. As part of a comprehensive prostate cancer care plan, it is often combined with hormonal therapy and regular follow-up by oncology specialists.
When used under expert medical supervision, Indenza provides an effective targeted treatment option for advanced prostate cancer. Strict adherence to the prescribed dosage and continuous communication with healthcare providers are essential to maximize therapeutic benefits and ensure safe, long-term treatment outcomes.

BDENZA 160 MG 
Composition: ENZALUTAMIDE 160 MG 
International Trade Name: Xtandi®

Bdenza 160 Enzalutamide (Xtandi) is an oral anticancer medication used for the treatment of advanced prostate cancer. It contains Enzalutamide 160 mg, a next-generation androgen receptor inhibitor that helps slow the growth and spread of prostate cancer cells. The reference brand Xtandi, developed by Astellas Pharma in partnership with Pfizer, is globally recognized for its effectiveness in prostate cancer therapy. Bdenza provides the same active ingredient and clinical benefits, produced under strict pharmaceutical quality standards for oncology care.
Enzalutamide works by blocking the activity of male hormones (androgens) that fuel prostate cancer growth. It prevents these hormones from binding to androgen receptors and interrupts the signals that encourage cancer cell multiplication. Through this targeted mechanism, Bdenza helps delay disease progression and supports better disease control in men with advanced prostate cancer. It is considered an important treatment option in modern hormone-targeted cancer therapy.
Bdenza 160 mg is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), as prescribed by an oncologist. The medicine is taken orally once daily, with or without food, preferably at the same time each day. Tablets should be swallowed whole with water and not crushed, broken, or chewed. The duration of treatment depends on the patient’s response and the doctor’s evaluation.
Patients using Bdenza require regular monitoring, including blood pressure checks and routine medical assessments, to ensure safe and effective treatment. Common side effects may include fatigue, weakness, hot flashes, dizziness, joint pain, and high blood pressure. In rare cases, seizures or serious nervous system effects may occur. Patients should immediately inform their healthcare provider if they experience unusual neurological symptoms, severe headaches, or confusion.
Important safety precautions should be followed. Bdenza is intended only for adult men and must not be used by women or children. Pregnant women should avoid contact with the medication, as it may harm an unborn baby. Men receiving treatment should use effective contraception during therapy and for a recommended period afterward. Patients with a history of seizures, cardiovascular disease, or liver disorders should inform their doctor before starting the medicine.
Bdenza 160 Enzalutamide tablets are supplied in protective packaging to maintain stability and potency and should be stored in a cool, dry place away from direct sunlight. The medication is manufactured according to recognized international pharmaceutical standards, ensuring consistent quality and reliability. As part of a comprehensive prostate cancer management plan, Bdenza is often used alongside hormonal therapy and ongoing oncology follow-up.
When taken under expert medical supervision, Bdenza offers an effective targeted therapy for managing advanced prostate cancer. Careful adherence to the prescribed dosage and regular communication with healthcare professionals are essential to maximize benefits and maintain patient safety throughout treatment.

AB-TYRA 500 Tablets
Composition: Abiraterone Acetate 500 mg Tablets
International Trade Name: Zytiga®

AB-TYRA 500 is a high-quality Abiraterone Acetate 500 mg tablet, a generic equivalent of the internationally recognized androgen biosynthesis inhibitor marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, AB-TYRA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of prostate cancer.

Abiraterone acetate is a potent, selective inhibitor of the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), which plays a critical role in androgen production. By suppressing androgen synthesis in the testes, adrenal glands, and tumor tissue, AB-TYRA 500 helps reduce circulating testosterone levels, thereby slowing tumor growth and disease progression. This targeted hormonal therapy is typically administered in combination with prednisone or prednisolone.

AB-TYRA 500 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), especially in patients who are receiving or have progressed on androgen deprivation therapy (ADT).

Abiraterone acetate 500 mg tablets, AB-TYRA tablets, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, hormonal oncology therapy, anticancer drug exporter India, and prostate cancer medicine manufacturer India.

AB-TYRA Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

AB-TYRA 250 mg Tablets
Composition: Abiraterone Acetate 250 mg Tablets IP
International Trade Name: Zytiga®

AB-TYRA 250 is a high-quality Abiraterone Acetate 250 mg tablet, a generic equivalent of the internationally recognized androgen biosynthesis inhibitor marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, AB-TYRA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of prostate cancer.

Abiraterone acetate is a potent, selective inhibitor of the CYP17 enzyme (17α-hydroxylase/C17,20-lyase), which is critical in androgen production. By suppressing androgen synthesis in the testes, adrenal glands, and tumor tissue, AB-TYRA 250 helps reduce testosterone levels and slow tumor growth and disease progression. This targeted hormonal therapy is typically administered in combination with prednisone or prednisolone.

AB-TYRA 250 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), especially in patients who are receiving or have progressed on androgen deprivation therapy (ADT).

Abiraterone acetate 250 mg tablets, AB-TYRA tablets, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, hormonal oncology therapy, anticancer drug exporter India, and prostate cancer medicine manufacturer India.

AB-TYRA Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

OLAPYRA 150 Tablets
Composition: Olaparib 150 mg
International Trade Name: Lynparza®

OLAPYRA 150 mg Tablets are a high-quality formulation of Olaparib, a potent poly (ADP-ribose) polymerase (PARP) inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Lynparza®. Manufactured in WHO-GMP certified facilities, OLAPYRA is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of BRCA-mutated cancers.

Olaparib works by inhibiting the PARP enzyme, which plays a critical role in DNA repair in cancer cells. By blocking DNA repair mechanisms, OLAPYRA induces apoptosis in cancer cells, especially in tumors with BRCA1 or BRCA2 mutations, making it an effective targeted therapy for patients with specific genetic profiles.

OLAPYRA 150 mg Tablets are primarily indicated for the treatment of BRCA-mutated ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, either as monotherapy or as maintenance therapy following response to platinum-based chemotherapy.

Olaparib 150 mg tablets, OLAPYRA tablets, Lynparza generic, PARP inhibitor, targeted oncology therapy, anticancer medicine exporter India, and pharmaceutical manufacturer India.

OLAPYRA Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

ABIRALIEVA Tablets
Composition: Abiraterone Acetate Tablets (250 mg / 500 mg – as applicable)
International Trade Name: Zytiga®

ABIRALIEVA is a high-quality Abiraterone Acetate formulation, a generic equivalent of the internationally recognized androgen biosynthesis inhibitor marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, ABIRALIEVA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in prostate cancer therapy.

Abiraterone acetate is a selective inhibitor of the CYP17 enzyme, which plays a crucial role in androgen production. By blocking androgen synthesis in the testes, adrenal glands, and tumor tissues, ABIRALIEVA helps reduce circulating androgen levels, thereby slowing tumor growth and disease progression in hormone-dependent prostate cancer.

ABIRALIEVA is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). It is commonly administered in combination with prednisone or prednisolone as part of a comprehensive hormonal therapy regimen.

Abiraterone acetate tablets, ABIRALIEVA, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, hormonal oncology therapy, anticancer tablets exporter India, and oncology pharmaceutical manufacturer India.

ABIRALIEVA Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Abiralieva 500mg Tablets
Composition: Abiraterone Acetate 500 mg Tablets
International Trade Name: Zytiga®

Abiralieva 500 is a high-quality Abiraterone Acetate 500 mg tablet, a generic equivalent of the internationally recognized androgen biosynthesis inhibitor marketed under the brand name Zytiga®. Manufactured in WHO-GMP certified facilities, Abiralieva Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in prostate cancer management.

Abiraterone acetate is a potent, selective inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase), a critical enzyme involved in androgen production. By suppressing androgen synthesis in the testes, adrenal glands, and tumor tissue, Abiralieva 500 mg Tablets help reduce tumor growth and disease progression in hormone-driven prostate cancer. This targeted hormonal therapy is commonly administered alongside prednisone or prednisolone.

Abiralieva 500 mg is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), especially in patients who have progressed on or are receiving androgen deprivation therapy (ADT).

Abiraterone acetate 500 mg tablets, Abiralieva tablets, Zytiga generic, prostate cancer treatment, androgen biosynthesis inhibitor, oncology tablets, anticancer drug exporter India, and hormonal therapy manufacturer India.

Abiralieva 500 Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Enzalutamide 80 mg Tablets
Composition: Enzalutamide 80 mg
International Trade Name: Xtandi®

Enzalutamide 80 mg Tablets are a high-quality formulation of Enzalutamide, a generic equivalent of the internationally recognized androgen receptor signaling inhibitor marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, these tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide is a potent, non-steroidal androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By inhibiting these mechanisms, Enzalutamide 80 mg helps prevent prostate cancer cell growth and proliferation, even in patients resistant to conventional androgen deprivation therapy.

These tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). Enzalutamide can be prescribed as monotherapy or alongside ongoing androgen deprivation therapy (ADT).

Enzalutamide 80 mg tablets, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Enzalutamide 80 mg Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Enzalutamide Capsules
Composition: Enzalutamide Capsules (40 mg / 80 mg – as applicable)
International Trade Name: Xtandi®

Enzalutamide Capsules are a high-quality formulation of enzalutamide, an advanced androgen receptor signaling inhibitor marketed internationally under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, these capsules are supplied by trusted pharmaceutical exporters from India to support global oncology treatment programs, particularly in the management of advanced prostate cancer.

Enzalutamide is a next-generation androgen receptor inhibitor that works by blocking multiple critical steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and interaction with DNA. This comprehensive mechanism effectively suppresses androgen-driven tumor growth, helping slow disease progression and improve treatment outcomes.

Enzalutamide Capsules are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). They are commonly prescribed in patients receiving androgen deprivation therapy (ADT) or those who have progressed on prior hormonal treatments.

Enzalutamide capsules, Xtandi, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer drug exporter India, and oncology pharmaceutical manufacturer India.

Enzalutamide Capsules are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Azel 160 mg Tablets
Composition: Enzalutamide 160 mg
International Trade Name: Xtandi®

Azel 160 mg Tablets are a high-quality formulation of Enzalutamide, a non-steroidal androgen receptor signaling inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Azel Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide works by blocking multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By effectively inhibiting these mechanisms, Azel 160 mg helps prevent prostate cancer cell proliferation and slows disease progression, even in patients resistant to conventional androgen deprivation therapy (ADT).

Azel 160 mg Tablets are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). They can be prescribed as monotherapy or in combination with ongoing ADT.

Enzalutamide 160 mg tablets, Azel, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Azel Tablets are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Enzamide 40 mg Capsules
Composition: Enzalutamide 40 mg
International Trade Name: Xtandi®

Enzamide 40 mg Capsules are a high-quality formulation of Enzalutamide, a generic equivalent of the internationally recognized androgen receptor signaling inhibitor marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Enzamide is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide is a potent, non-steroidal androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By effectively inhibiting these mechanisms, Enzamide 40 helps prevent prostate cancer cell growth and proliferation, even in patients resistant to conventional androgen deprivation therapy.

Enzamide 40 mg Capsules are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). They can be prescribed as monotherapy or in combination with ongoing androgen deprivation therapy (ADT).

Enzalutamide 40 mg capsules, Enzamide, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Enzamide is manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Enzaneal 40 mg Capsules/Tablets
Composition: Enzalutamide 40 mg
International Trade Name: Xtandi®

Enzaneal 40 is a high-quality Enzalutamide 40 mg formulation, a generic equivalent of the internationally recognized androgen receptor signaling inhibitor marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Enzaneal is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide is a potent, non-steroidal androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By effectively inhibiting these mechanisms, Enzaneal 40 helps prevent prostate cancer cell growth and proliferation, even in patients resistant to conventional androgen deprivation therapy.

Enzaneal 40 mg is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). It can be prescribed as monotherapy or in combination with ongoing androgen deprivation therapy (ADT).

Enzalutamide 40 mg capsules, Enzaneal, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Enzaneal is manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Enzanamo 40 mg Capsules/Tablets
Composition: Enzalutamide 40 mg
International Trade Name: Xtandi®

Enzanamo 40 is a high-quality Enzalutamide 40 mg formulation, a generic equivalent of the internationally recognized androgen receptor inhibitor marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Enzanamo is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide is a potent, non-steroidal androgen receptor signaling inhibitor that works by blocking multiple steps in the androgen receptor pathway, including androgen binding, nuclear translocation, and DNA transcription. By inhibiting these mechanisms, Enzanamo 40 effectively suppresses prostate cancer cell proliferation and slows disease progression, even in cases resistant to conventional androgen deprivation therapy.

Enzanamo 40 mg is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). It is commonly prescribed as monotherapy or in combination with ongoing androgen deprivation therapy (ADT).

Enzalutamide 40 mg capsules, Enzanamo, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Enzanamo is manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Azel 80 mg Capsules
Composition: Enzalutamide 80 mg
International Trade Name: Xtandi®

Azel 80 mg Capsules are a high-quality formulation of Enzalutamide, a potent non-steroidal androgen receptor inhibitor, and a generic equivalent of the internationally recognized product marketed under the brand name Xtandi®. Manufactured in WHO-GMP certified facilities, Azel is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in the management of advanced and metastatic prostate cancer.

Enzalutamide works by blocking multiple steps in the androgen receptor signaling pathway, including androgen binding, nuclear translocation, and DNA transcription. By effectively inhibiting these mechanisms, Azel prevents prostate cancer cell proliferation and slows disease progression, even in patients resistant to conventional androgen deprivation therapy (ADT).

Azel 80 mg Capsules are primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). It can be prescribed as monotherapy or in combination with ongoing ADT.

Enzalutamide 80 mg capsules, Azel capsules, Xtandi generic, prostate cancer treatment, androgen receptor inhibitor, hormonal oncology therapy, anticancer medicine exporter India, and prostate cancer drug manufacturer India.

Azel Capsules are manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Taxonab 100 mg Injection
Composition: Paclitaxel 100 mg
International Trade Name: Taxol®

Taxonab 100 mg Injection is a high-quality formulation of Paclitaxel, a chemotherapeutic agent widely used in oncology, and a generic equivalent of the internationally recognized product marketed under the brand name Taxol®. Manufactured in WHO-GMP certified facilities, Taxonab Injection is supplied by trusted pharmaceutical exporters from India to support advanced global cancer treatment programs.

Paclitaxel is a mitotic inhibitor that works by stabilizing microtubules and preventing their depolymerization, thereby inhibiting cell division. By targeting rapidly dividing cancer cells, Taxonab 100 mg effectively slows tumor growth and progression across a variety of malignancies.

Taxonab 100 mg Injection is primarily indicated for the treatment of breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), Kaposi’s sarcoma, and other solid tumors, either as monotherapy or in combination with other chemotherapeutic agents, depending on clinical protocols.

Paclitaxel 100 mg injection, Taxonab injection, Taxol generic, anticancer chemotherapy, oncology infusion therapy, cancer treatment injectable, anticancer drug exporter India, and pharmaceutical manufacturer India.

Taxonab 100 mg Injection is manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Dutaxel 100 mg Injection
Composition: Paclitaxel 100 mg
International Trade Name: Taxol®

Dutaxel 100 mg Injection is a high-quality formulation of Paclitaxel, a chemotherapeutic agent widely used in oncology, and a generic equivalent of the internationally recognized product marketed under the brand name Taxol®. Manufactured in WHO-GMP certified facilities, Dutaxel Injection is supplied by trusted pharmaceutical exporters from India to support advanced global cancer treatment programs.

Paclitaxel is a mitotic inhibitor that stabilizes microtubules and prevents their depolymerization, thereby inhibiting cell division. By targeting rapidly dividing cancer cells, Dutaxel 100 mg Injection effectively slows tumor growth and progression across a variety of malignancies.

Dutaxel 100 mg Injection is primarily indicated for the treatment of breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), Kaposi’s sarcoma, and other solid tumors, either as monotherapy or in combination with other chemotherapeutic agents, depending on clinical protocols.

Paclitaxel 100 mg injection, Dutaxel injection, Taxol generic, anticancer chemotherapy, oncology infusion therapy, cancer treatment injectable, anticancer drug exporter India, and pharmaceutical manufacturer India.

Dutaxel 100 mg Injection is manufactured under stringent GMP and international pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.